U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H17ClN2O2
Molecular Weight 292.761
Optical Activity ( + / - )
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LORTALAMINE

SMILES

[H][C@@]12CN(C)CC[C@@]13NC(=O)C[C@@H]2C4=CC(Cl)=CC=C4O3

InChI

InChIKey=MJRPHRMGEKCADU-GMXABZIVSA-N
InChI=1S/C15H17ClN2O2/c1-18-5-4-15-12(8-18)10(7-14(19)17-15)11-6-9(16)2-3-13(11)20-15/h2-3,6,10,12H,4-5,7-8H2,1H3,(H,17,19)/t10-,12+,15+/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H17ClN2O2
Molecular Weight 292.761
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Lortalamine is a new non-tricyclic anti-depressant compound. Lortalamine antagonizes in a dose-related manner reserpine-induced ptosis and hypothermia, and is far more potent than imipramine in this regard. The compound potentiates yohimbine toxicity in mice and, in the anesthetized dog, diminishes the tyramine pressure response while increasing the response to norepinephrine. These results would indicate the capacity for lortalamine to act as a norepinephrine uptake inhibitor, and indeed, lortalamine is more potent than imipramine in inhibiting norepinephrine uptake by rat brain cortex slices. Lortalamine does not inhibit serotonin uptake by rat midbrain slices. Lortalamine has a high affinity and high selectivity for the norepinephrine transporter. Lortalamine treated dogs showed, progressively, bilateral mydriasis, conjunctivitis, epiphora, corneal oedema and corneal erosions.

Originator

Approval Year

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
10 mg/kg/day once a day, 7 days a week for, respectively, 7 and 91 days.
Route of Administration: Oral
Substance Class Chemical
Record UNII
9GIR4SV22T
Record Status Validated (UNII)
Record Version